Tag
This study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.
This article discusses the role of cyclin D1 (CCND1) in promoting reparative macrophage transition post-myocardial infarction, highlighting its therapeutic potential in reducing adverse cardiac remodeling through metabolic reprogramming.
Nighttime light exposure over 3 lux is linked to adverse cardiac remodeling, subclinical functional decline, and increased cardiovascular events, partly mediated by shorter sleep duration, underscoring the importance of dark nights and slee
The LUMINARA trial evaluates AZD5462, an oral relaxin receptor agonist, demonstrating safety and promising effects on cardiac remodeling and vascular resistance in chronic heart failure, warranting further large-scale investigation.
Lower ventricular chamber stiffness predicts adverse outcomes in Fontan patients, revealing a high-compliance, eccentric remodeling phenotype distinct from traditional stiffening hypotheses.
This study identifies RUNX1-mediated endothelial-to-mesenchymal transition as a key driver of myocardial fibrosis and remodeling in LMNA cardiomyopathy, highlighting potential therapeutic avenues targeting endothelial RUNX1 signaling.
This study reveals that 21% of asymptomatic patients with mild HCM develop major adverse cardiovascular events over 7 years, highlighting key predictors such as age, symptom progression, and cardiac remodeling markers that inform management
A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.
The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in p
A landmark study reveals that former world-class rowers face a seven-fold higher risk of atrial fibrillation compared to the general population, driven by a combination of intensive cardiac remodeling and a strong polygenic predisposition.
In the CARDIA cohort, higher carbohydrate quality (lower carbohydrate:fibre ratio) and greater intake of fibre-rich foods were associated with more favorable left ventricular structure and function measured 25–30 years after baseline diet a
Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.
This study reveals that excess adiposity, rather than insulin resistance or diabetes, predominantly drives left heart abnormalities and elevated pulmonary pressures in HFpEF, highlighting the need for targeted cardiometabolic therapies beyo
Aficamten shows sustained obstruction relief, symptom improvement, and favorable cardiac remodeling over 48 weeks in obstructive hypertrophic cardiomyopathy, with safe discontinuation of disopyramide possible.
